Agilent’s contract Lead Discovery Service utilizes label-free RapidFire technology for direct quantitation of a wide range of native analytes across diverse therapeutic areas. Supports SAR programs via retesting of hits. Uses your existing assays or RapidFire custom-developed assays. Quick data turnaround for faster drug discovery decisions.
Screened as singletons or compressed format
The ideal candidate assays are often the same ones that are difficult to screen using traditional HTS techniques. These include enzymatic targets that have lipidic or very small substrates, epigenetic targets and others.